wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww

Background Image

AN ESTABLISHED & GROWING PRODUCT PORTFOLIO

Solutions that support patient needs

CONTACT US

Products

Therapy Area

  • Analgesia
    Product nameProduct description
    OxyContin®Oxycodone Hydrochloride, extended-release tablets
    OxyNorm®Oxycodone Hydrochloride, immediate-release
    TarginActTMOxycodone Hydrochloride and Naloxone Hydrochloride, prolonged-release
    BuTrans®Buprenorphine transdermal patch
    MST Continus®Prolonged Release Morphine Sulphate
    MSITMMorphine Sulphate Injection
    Tramundin®Tramadol Hydrochloride Tablets
    TranstecTMBuprenorphine transdermal patch
  • Oncology and Oncology Supportive Care
    PRODUCT NAMEPRODUCT Description
    FotolynTMPralatrexate Solution for intravenous injection
    DepocyteTMCytarabine liposome injection
    Akynzeo®Netupitant and Palonosetron capsules
    Aloxi®Palonosetron capsules / solution for injection
    Zevalin®Ibritumomab Tiuxetan Intravenous Injection
  • Ophthalmology
    PRODUCT NAMEPRODUCT DESCRIPTION
    Trusopt® Ophthalmic SolutionDorzolamide Hydrochloride 2%
    Cosopt® Ophthalmic SolutionDorzolamide Hydrochloride 20 mg/ml (+)
    Timolol Maleate 5 mg/ml
    Cosopt PF® Ophthalmic SolutionDorzolamide Hydrochloride 20 mg/ml (+)
    Timolol Maleate 5 mg/ml
    Saflutan® Ophthalmic SolutionTafluprost 15 mcg/ml
    Timoptol® 0.50% Ophthalmic SolutionTimolol Maleate 0.50%
    Timoptol® XE 0.5% Ophthalmic SolutionTimolol Maleate 0.50%
  • Respiratory
    PRODUCT NAMEPRODUCT DESCRIPTION
    FlutiformTMFormeterol Fumerate and Fluticasone Proprionate
  • Consumer Healthcare
    Product NameProduct Description
    BETADINE® RepiGelHydrogel with Povidone-Iodine (3%) and Liposomal Delivery System
    BETADINE®Povidone-Iodine
  • Wound Dressing
    Product NameProduct Description
    BETAplastTM BHydrophilic Foam Dressing Non-Adhesive
    BETAplastTM HHydrocolloid Dressing Adhesive
    BETAplastTM NHydrophilic Foam Dressing Non-Adhesive
    BETAplastTM FHydrophilic Foam Dressing with Film Adhesive
    BETAplastTM SilverAntimicrobial Foam Dressing Non-Adhesive

® OxyContin, OxyNorm, BuTrans, MST Continus, Tramundin, Betadine,Timoptol, Trusopt, Cosopt, & Saflutan are registered trademarks of Mundipharma AG in UAE and are either registered trademarks or trademarks in other countries.

™ TarginAct, MSI, Transtec, BETAplast, Repigel, BurnAid, WoundAid, Folotyn, Flutiform, Depocyte are trademarks of Mundipharma AG in UAE and are either registered trademarks or trademarks in other countries.

® Zevalin is a registered trademark of Bayer Schering Pharma AG in UAE and is a trademark or registered trademark in other countries.

® Akynzeo and Aloxi are registered trademarks in UAE and are trademarks or registered trademarks in other countries, of Helsinn Healthcare SA, Switzerland, used under license.

Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities

* Not all products or indications are available in all countries. Products are currently under registrations across Middle East and Africa Region and subject to approval according to local laws and regulations.

Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for readers from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.

Analgesia

Analgesia is by far our largest area of expertise. Over the past 60 years, Mundipharma has introduced a number of products that have transformed the way pain is treated, offering oral, transdermal and parenteral delivery of analgesia to suit patient needs.

 

The product range includes:

OxyNorm® ® formulations– capsules, liquid, concentrate immediate-release formulations that contain the active ingredient oxycodone. Indicated for the treatment of moderate to severe pain in patients with cancer and post-operative pain. For the treatment of severe pain requiring the use of a strong opioid.

OxyNorm® Injection is indicated for the treatment of moderate to severe pain in patients with cancer and post-operative pain. For the treatment of severe pain requiring the use of a strong opioid.

TranstecTM – a transdermal patch containing buprenorphine.

TarginActTM tablets, a prolonged-release oral combination of the opioid agonist oxycodone and the opioid antagonist naloxone, is a recent addition to the oxycodone range. Indicated for severe pain, which can be adequately managed only with opioid analgesics.

The opioid antagonist naloxone is added to counteract opioid-induced constipation by blocking the action of oxycodone at opioid receptors locally in the gut.

MST® Continus® film-coated tablets contain morphine sulfate. Indicated for the prolonged relief of severe pain.

MSITM solution for injection contains morphine sulfate. Indicated for severe and most severe pain.

BuTrans® is a transdermal patch that delivers a constant dose of buprenorphine during seven days of wear. Indicated for the treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate pain.

Tramundin® prolonged release tablets have the active ingredient tramadol. Indicated for the management of moderate to severe analgesia.

® OxyContin, OxyNorm, BuTrans, MST Continus, Tramundin are registered trademarks of Mundipharma AG in UAE and are either registered trademarks or trademarks in other countries.

™ TarginAct, MSI & Transtec are trademarks of Mundipharma AG in UAE and are either registered trademarks or trademarks in other countries.

Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities

* Not all products or indications are available in all countries. Products are currently under registrations across Middle East and Africa Region and subject to approval according to local laws and regulations.

Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for r eaders from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.

Background Image

Oncology and Oncology Supportive Care

Mundipharma aims to improve the health and quality of life of patients everywhere with innovative products that meet their needs and the needs of the health care professionals. Mundipharma’s cancer treatment and cancer supportive care portfolio includes products for treating neuro-oncological and haematological malignancies, managing chemotherapy induced nausea and vomiting and cancer – cachexia.

 

FolotynTM (pralatraxate), a folate analogue metabolic inhibitor, is the first FDA approved drug for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), a biologically diverse group of aggressive blood cancers.

DepocyteTM (liposomal cytarabine) – A sustained-release injectable formulation of cytarabine for the treatment of lymphomatous meningitis, a serious late-stage complication of lymphoma.

Aloxi® (Palonosetron) is a 5-HT3 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting (CINV) and is available in i.v. formulation. It is indicated for prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy in adults.

Akynzeo® – An oral combination of netupitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV)

Zevalin® – a CD20-directed radiolabeled antibody injection (to be administered after rituximab).

FolotynTM & Depocyte™ are trademarks of Mundipharma AG in UAE and are either registered trademarks or trademarks in other countries.

Akynzeo® and Aloxi® are registered trademarks in UAE and are trademarks or registered trademarks in other countries, of Helsinn Healthcare SA, Switzerland, used under license.

Zevalin® is a registered trademark of Bayer Schering Pharma AG in UAE and is a trademark or registered trademark in other countries.

Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities

* Not all products or indications are available in all countries. Products are currently under registrations across Middle East and Africa Region and subject to approval according to local laws and regulations.

Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for readers from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.

Background Image

Ophthalmology

Our ophthalmology portfolio consists of a full range of eye drops products dedicated to the chronic treatment of patients with primitive open angle glaucoma, the most predominant glaucoma type in the world.

The product range includes:

Timoptol®, Timopotol XE®, and Timoptol® Preservative Free –contains the active ingredient timolol maleate, which is a beta-blocker agent used as anti-glaucoma treatment either in a monotherapy regimen or associated with another anti-glaucoma agent

Saflutan®– Preservative-Free eye drops that contain the active ingredient tafluprost, which is a prostaglandin analogue, and is used as anti-glaucoma therapy either in a monotherapy regimen or associated with another anti-glaucoma agent

Trusopt® and Trusopt® Preservative-Free – eye drops that contain the active ingredient dorzolamide hydrochloride, which is a carbonic anhydrase inhibitor, and is used as anti-glaucoma treatment either in a monotherapy regimen or associated with another anti-glaucoma agent

Cosopt® and Cosopt®-Free– eye drops that contain the fix-dose combination of active ingredient timolol maleate and dorzolamide hydrochloride, which combines a beta-blocker and a carbonic anhydrase inhibitor used as anti-glaucoma agents

® Timoptol, Trusopt, Cosopt & Saflutan are registered trademarks of Mundipharma AG in UAE and are either registered trademarks or trademarks in other countries.

Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities

* Not all products or indications are available in all countries. Products are currently under registrations across Middle East and Africa Region and subject to approval according to local laws and regulations.

Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for readers from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.

Background Image

Respiratory

Mundipharma is committed to developing innovative therapeutic solutions that will make a true impact on the daily lives of millions of sufferers of respiratory diseases across the world.

The product range includes:

FlutiformTM (fluticasone/formoterol) combines fluticasone an inhaled corticosteroid with formoterol fumarate, a long-acting β2 agonist in a single HDI (High Deposition Inhaler) device, which delivers an aerosol of fine particles at a consistent dose.

TM Flutiform is a trademark of Mundipharma AG in UAE and is either registered trademark or trademark in other countries.

Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities

* Not all products or indications are available in all countries. Products are currently under registrations across Middle East and Africa Region and subject to approval according to local laws and regulations.

Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for readers from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.

Consumer Healthcare

Produced by Mundipharma, BETADINE® has a track record of over 50 years in providing broad spectrum antiseptics to consumers in the categories of wound care, oral and female hygiene, among others. Betadine® Antiseptics are widely used in hospitals, doctors’ surgeries, sports medicine clinics and veterinarian clinics. A real advantage of the Betadine® range is its key ingredient povidone-iodine, which has the power of traditional iodine but does not sting or irritate nearly as much1. The Betadine® range uses the powerful action of iodine against a range of bacteria, viruses and fungi 2-3.

 

The product range includes:

BETADINE®  has three main categories of products with over 10 different formats to meet the varying needs of our customers.

BETADINE® ORAL CARE  rapidly kills the three groups of organisms that cause throat infections – bacteria, viruses, and fungi, in as fast as 30 seconds 4 . It is effective in killing the viruses that cause avian flu, common flu, and common colds4-6.

BETADINE® FEMININE CARE
BETADINE®  has effective medicated products for treating a wide range of vaginal infections. By killing germs such as bacteria, fungi, and protozoa which cause vaginal infection, BETADINE®  helps relieve vaginal infection symptoms such as vaginal discomfort, abnormal discharge, odour and itchiness7-10.

For more than 50 years, BETADINE® products have found widespread acceptance in hospitals and homes around the world as an important first line of defense against topical infections. Over the years, the brand’s portfolio has grown to offer a complete range of antiseptic solutions that address the specialized requirements of doctors and households.

The origins of BETADINE® dates back to 1952 and the creation of this new treatment was significant as it represented the next major improvement in medicinal iodine compounds in the last 100 years.

Iodine is an age old antiseptic. However, by itself it does not dissolve in water and can be unstable. Traditionally, pharmacists had to add up to 70% of alcohol to create medications. The high content of alcohol posed a problem as it slowed down the rate of healing for wounds.

A new, safe, easy to handle and effective treatment was born with the addition of PVP that got rid of the alcohol. This marked the beginnings of the BETADINE® success story. Today, PVP-I is a high-quality iodine owned by BETADINE® that is distributed and sold globally.

BETADINE Dry Powder Spray is a new, easier way to treat minor wounds at home. It’s no touch, no drip and easy to carry – giving mothers the confidence to deal with any emergency easily.

1960s
Povidone-iodine preparation, an upgraded iodine based antiseptic formulation, was discovered. Its slow release of iodine within the formula was found to improve product stability, reduce the sting and irritation of traditional iodine treatments. It quickly became the universally preferred iodine disinfectant.

1963
BETADINE® is registered as a trademark and launched in several international markets.

1969
BETADINE® antiseptic was chosen by NASA to wipe down the Apollo 11 spacecraft when it landed back on earth after a successful trip to the moon to remove any space germs that might have hitched a ride.

® Betadine is registered trademarks of Mundipharma AG in UAE and is either registered trademark or trademark in other countries.

Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities

* Not all products or indications are available in all countries. Products are currently under registrations across Middle East and Africa Region and subject to approval according to local laws and regulations.

Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for readers from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.

1. Ripa S. et all.Clinical applications of povidone-iodine as a topical antimicrobial. In: Paulson DS, ed. Handbook of Topical Antimicrobials: Industrial Applications in Consumer Products and Pharmaceuticals. NewYork: Marcel Dekker, 2003: 77–98.
2. Mayer DA, et al. Wounds: A Compendium of Clinical Research and Practice. 1993; 5(1): 14-23
3.Fleischer W et al. Dermatology 1997;195(suppl 2) :3-9
4. Kawana R et al. Dermatology 1997;195(suppl 2)29-35.
5. Kariwa H, et al. Dermatology 2004; 212(suppl 1): 119-123.
6. Beaton et al. Int. J. Fertil 29(2), 1984, p. 109-112
7. Monif GR, et al. Am J Obstet Gynecol. 1980;137:432–438
8. Gunther WewaIka et al. Dermatology 2002; 204(suppl 1): 79-85
9. S Maneksha. J Int Med Res 1974; 2: 236-239
10.Resch BA, et al. Ther Hung. 1993;41(4):137–140.

Wound Dressing

The BETAplast®  wound dressing range of products can be used to treat minor cuts, wounds, grazes and burns, and are available in a variety of convenient formats making them suitable for use at home and outdoors.

The BETAplast dressing is a triple-layered hydrophilic polyurethane foam dressing that has been in clinical use for more than 12 years.

The BETAplast products, which feature SMARTPORE Technology, are specially designed for an optimal moist wound environment, which has been shown to promote proper wound healing.

Each BETAplast product also features specific properties suited to various indications.

Polyurethane foam products: BETAplast N, B, F, Silver

Hydrocolloid products: BETAplast H

products-side-cons2

™ BETAplast is a trademarks of Mundipharma AG in UAE and are either registered trademark or trademark in other countries.

Please refer to individual countries for full local prescribing information and indications as approved by relative health authorities

* Not all products or indications are available in all countries. Products are currently under registrations across Middle East and Africa Region and subject to approval according to local laws and regulations.

Please refer to your local representative office and the locally approved prescribing information for more details on the product and indications. Furthermore, Mundipharma Middle East FZLLC provides the information for readers from many countries in the ME region as of this date and does not undertake any obligation to update any forward-looking statements contained in this newsletter as a result of new information, future events or otherwise.

↓
WordPress Video Lightbox Plugin